Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ardizzoni, A.; Salvati, F.; Rosso, R.; Bruzzi, P.; Rubagotti, A.; Pennucci, M. C.; Mariani, G. L.; DeMarinis, F.; Pallotta, G.; Antilli, A.; Cruciani, A. M.; Tonachella, R.; Fioretti, M.; Barbera, S.; Mantellini, E.; Soresi, E.; Pastorino, G.; Belli, M.; Ferrara, G.; Venturini, M.; Scagliotti, G.; Sauti, L.; Italian Lung Cancer Task Force. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. Cancer 1993;72:2929–2935; 1993.
Andrews, 1990, The abdominal visceral innervation and the emetic reflex, Can. J. Physiol. Pharmacol., 68, 325, 10.1139/y90-047
Andrews, 1986, Apomorphine-induced vomiting in the ferret, Br. J. Pharmacol., 89, 860P
Andrews, 1987, Abdominal vagotomy modifies the emetic response to radiation in the ferret, J. Physiol. (Lond.), 378, 16P
Andrews, 1988, The neurophysiology of vomiting, Baillieres Clin. Gastroenterol., 2, 141, 10.1016/0950-3528(88)90025-5
Andrews, 1988, Vagally mediated gastric motor and emetic reflexes evoked by stimulation of antral mucosa in anesthetized ferrets, J. Physiol. (Lond.), 395, 1, 10.1113/jphysiol.1988.sp016905
Beutner, 1997, Imiquimod-an immune response modifier for treatment of external genital warts, Todays Therapeutic Trends, 15, 165
Beutner, 1998, Imiquimod, a patient applied immune-response modifier for treatment of external warts, Antimicrob. Agents Chemother., 42, 789, 10.1128/AAC.42.4.789
Borison, 1985, A misconception of motion sickness leads to false therapeutic expectations, Aviat. Space Environ. Med., 56, 66
Brizzee, 1980, Effect of ablation of the area postrema on frequency and latency of motion sickness-induced emesis in the squirrel monkey, Physiol. Behav., 24, 849, 10.1016/0031-9384(80)90139-0
Cammermeyer, 1972, Mast cells in the mammalian area postrema, Z. Anat. Entwicklungsgesch., 131, 71, 10.1007/BF00520946
Carpenter, 1989, Central nervous system mechanisms in deglutition and emesis, 685
Carpenter, 1983, Responses of neurons of canine area postrema to neurotransmitters and peptides, Cell. Mol. Neurol., 3, 113, 10.1007/BF00735276
Carpenter, 1984, Peptide-induced emesis in the dog, Behav. Brain Res., 11, 277, 10.1016/0166-4328(84)90220-1
Carpenter, 1984, Behavioral and electrophysiological studies of peptide-induced emesis in dogs, Fed. Proc., 43, 16
Costall, 1989, The responsiveness of the ferret to apomorphine induced emesis, Br. J. Pharmacol., 96, 329P
D’Amelio, 1985, Immunocytochemical localization of glial fibrillary acidic protein (GFAP) in the area postrema of the cat. Light and electron microscope study, Brain Res., 330, 146, 10.1016/0006-8993(85)90016-2
Edwards, L. Imiquimod in clinical practice. Australas. J. Dermatol. 59(suppl.):S14–S16; 1998.
Edwards, 1998, Self-administered topical 5% imiquimod cream for external anogenital warts, Arch. Dermatol., 134, 25, 10.1001/archderm.134.1.25
Florczyk, 1982, Cisplatin-induced emesis in the ferret, Cancer Treat. Rep., 66, 187
Gylys, 1988, BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties, J. Pharmacol. Exp. Ther., 244, 830
King, 1988, Characterization of radiation-induced emesis in the ferret, Radiat. Res., 114, 599, 10.2307/3577130
King, 1990, Animal models in the study of emesis, Can. J. Physiol. Pharmacol., 68, 260, 10.1139/y90-040
Klara, 1975, The ultrastructural morphology of the squirrel monkey area postrema, Cell Tissue Res., 160, 315, 10.1007/BF00222042
Klara, 1977, Ultrastructure of the feline area postrema, J. Comp. Neurol., 171, 409, 10.1002/cne.901710307
Knox, 1993, Behavioral studies of emetic sensitivity in the ferret, Brain Res. Bull., 31, 477, 10.1016/0361-9230(93)90112-O
Knox, 1994, The central connections of the vagus nerve in the ferret, Brain Res. Bull., 33, 49, 10.1016/0361-9230(94)90048-5
Migita, 1998, Effects of arginine-vasopressin on neuronal interaction from the area postrema to the nucleus tractus solitarii in rat brain slices, Neurosci. Lett., 30, 45, 10.1016/S0304-3940(98)00753-8
Miller, 1994, The area postrema and vomiting, Front. Neuroendocrinol., 15, 301, 10.1006/frne.1994.1012
Miller, 1999, Imiquimod applied topically, Int. J. Immunopharmacol., 21, 1, 10.1016/S0192-0561(98)00068-X
Reiter, 1994, Cytokine induction in mice by the immunomodulator imiquimod, J. Leukocyte Biol., 55, 234, 10.1002/jlb.55.2.234
Sidky, 1992, Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine, Cancer Res., 52, 3528
Slade, 1998, Imiquimod 5% cream (Aldara TM), Exp. Opin. Invest. Drugs, 7, 437, 10.1517/13543784.7.3.437
Tyring, 1998, Immune response modification, Australas. J. Dermatol., 59, S11
Wagner, 1997, Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463, Cytokine, 9, 837, 10.1006/cyto.1997.0239
Wang, 1980
Wang, 1950, The vomiting center, Arch. Neurol. Psychiaty, 3, 928, 10.1001/archneurpsyc.1950.02310240087005
Wang, 1952, A new concept of organization of the central emetic mechanism, Gastroenterology, 22, 1, 10.1016/S0016-5085(19)36357-7
Wang, 1954, Experimental motion sickness in dogs. Functional importance of chemoreceptive emetic trigger zone, Am. J. Physiol., 178, 111, 10.1152/ajplegacy.1954.178.1.111
Wisloff, 1996, Effect of interferon on the health-related quality of life of multiple myeloma patients: Results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group, Br. J. Haematol., 94, 324, 10.1046/j.1365-2141.1996.d01-1802.x
Witt, 1993, Phase I trial of an oral immunomodulator and interferon inducer in cancer patients, Cancer Res., 53, 5176